Cargando…

Immunologic Responses After COVID-19 Vaccination in Patients With Membranous Nephropathy Receiving Anti–CD38 Felzartamab Therapy: Results From the Phase 1b/2a M-PLACE Study

Detalles Bibliográficos
Autores principales:	Rovin, Brad H., Boxhammer, Rainer, Thakur, Anjali, Ronco, Pierre M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9186646/ https://www.ncbi.nlm.nih.gov/pubmed/35702397 http://dx.doi.org/10.1016/j.ekir.2022.05.031

Ejemplares similares

Safety, tolerability, and efficacy of monoclonal CD38 antibody felzartamab in late antibody-mediated renal allograft rejection: study protocol for a phase 2 trial
por: Mayer, Katharina A., et al.
Publicado: (2022)

Membranous Nephropathy With Crescents
por: Alawieh, Rasha, et al.
Publicado: (2020)

Immune response to SARS-CoV-2 infection and vaccination in patients receiving kidney replacement therapy
por: Ikizler, T. Alp, et al.
Publicado: (2021)

Advances in Membranous Nephropathy
por: Ronco, Pierre, et al.
Publicado: (2021)

Immunology of membranous nephropathy
por: Akiyama, Shin'ichi, et al.
Publicado: (2019)

Kidney International and the COVID-19 infection
por: Rovin, Brad H., et al.
Publicado: (2020)

Membranous nephropathy: current understanding of various causes in light of new target antigens
por: Ronco, Pierre, et al.
Publicado: (2021)

Anticoagulant-Related Nephropathy in Kidney Biopsy: A Single-Center Report of 41 Cases
por: Brodsky, Sergey V., et al.
Publicado: (2019)

Clinical Outcomes in Patients With Biopsy Proven Anticoagulant-Related Nephropathy
por: Dasgupta, Alana, et al.
Publicado: (2023)

Establishing a Case for Anti-complement Therapy in Membranous Nephropathy
por: Ayoub, Isabelle, et al.
Publicado: (2020)

The Role of PLA2R Antibody in Treatment of Membranous Nephropathy
por: Dahan, Karine, et al.
Publicado: (2017)

Role of glomerular filtration rate‐modifying drugs in the development of anticoagulant‐related nephropathy
por: Medipally, Ajay K., et al.
Publicado: (2021)

Gross hematuria following vaccination for severe acute respiratory syndrome coronavirus 2 in 2 patients with IgA nephropathy
por: Negrea, Lavinia, et al.
Publicado: (2021)

The place of cyclical therapy for the treatment of membranous nephropathy in the era of rituximab
por: Alberici, Federico, et al.
Publicado: (2023)

Early experience with COVID-19 in kidney transplantation
por: Coates, P. Toby, et al.
Publicado: (2020)

Rituximab in Patients With Primary Membranous Nephropathy With High Immunologic Risk
por: Naik, Sachin, et al.
Publicado: (2023)

Long-Term Follow-Up of Cyclical Cyclophosphamide and Steroids Versus Tacrolimus and Steroids in Primary Membranous Nephropathy
por: Ramachandran, Raja, et al.
Publicado: (2021)

Anticoagulant Related Nephropathy Only Partially Develops in C57BL/6 Mice: Hematuria Is Not Accompanied by Red Blood Cell Casts in the Kidney
por: Medipally, Ajay K., et al.
Publicado: (2021)

Proteomic Analysis of Complement Proteins in Membranous Nephropathy
por: Ravindran, Aishwarya, et al.
Publicado: (2020)

Implementing the Kidney Health Initiative Surrogate Efficacy Endpoint in Patients With IgA Nephropathy (the PROTECT Trial)
por: Barratt, Jonathan, et al.
Publicado: (2019)

Why Target the Gut to Treat IgA Nephropathy?
por: Barratt, Jonathan, et al.
Publicado: (2020)

Pathophysiological lessons from rare associations of immunological disorders
por: Ronco, Pierre, et al.
Publicado: (2009)

HLA Desensitization in Solid Organ Transplantation: Anti-CD38 to Across the Immunological Barriers
por: Joher, Nizar, et al.
Publicado: (2021)

Long-Term Safety, Clinical and Immunological Outcomes in Primary Membranous Nephropathy with Severe Renal Impairment Treated with Cyclophosphamide and Steroid-Based Regimen
por: Ragy, Omar, et al.
Publicado: (2023)

α-Radioimmunotherapy with (213)Bi-anti-CD38 immunoconjugates is effective in a mouse model of human multiple myeloma
por: Teiluf, Katharina, et al.
Publicado: (2014)

Acute kidney injury aggravated by treatment initiation with apixaban: Another twist of anticoagulant-related nephropathy
por: Brodsky, Sergey V., et al.
Publicado: (2017)

Rituximab in Patients With Phospholipase A2 Receptor–Associated Membranous Nephropathy and Severe CKD
por: Hanset, Nicolas, et al.
Publicado: (2019)

Immunological Pathogenesis of Membranous Nephropathy: Focus on PLA2R1 and Its Role
por: Liu, Wenbin, et al.
Publicado: (2019)

Predictive Models for Recurrent Membranous Nephropathy After Kidney Transplantation
por: Chung, Edmund Y. M., et al.
Publicado: (2022)

Immunological Pattern in IgA Nephropathy
por: Esteve Cols, Clara, et al.
Publicado: (2020)

The Exostosin Immunohistochemical Status Differentiates Lupus Membranous Nephropathy Subsets With Different Outcomes
por: Saïdi, Michèle, et al.
Publicado: (2021)

Efficacy and Safety of Rituximab in Hepatitis B Virus–Associated PLA2R-Positive Membranous Nephropathy
por: Berchtold, Lena, et al.
Publicado: (2017)

Safety, Tolerability and Efficacy of Narsoplimab, a Novel MASP-2 Inhibitor for the Treatment of IgA Nephropathy
por: Lafayette, Richard A., et al.
Publicado: (2020)

Serum Protein Signatures Using Aptamer-Based Proteomics for Minimal Change Disease and Membranous Nephropathy
por: Muruve, Daniel A., et al.
Publicado: (2022)

Safety and Efficacy of Combination ACTHar Gel and Tacrolimus in Treatment-Resistant Focal Segmental Glomerulosclerosis and Membranous Glomerulopathy
por: Tumlin, James, et al.
Publicado: (2017)

Development of a Standardized Chemiluminescence Immunoassay for the Detection of Autoantibodies Against Human M-Type Phospholipase A2 Receptor in Primary Membranous Nephropathy
por: Dähnrich, Cornelia, et al.
Publicado: (2019)

Immunological abnormalities in patient with IgA nephropathy.
por: Ihm, C. G., et al.
Publicado: (1986)

Rituximab Treatment for Membranous Nephropathy: A French Clinical and Serological Retrospective Study of 28 Patients
por: Michel, Pierre-Antoine, et al.
Publicado: (2011)

Circulating (CD3(−)CD19(+)CD20(−)IgD(−)CD27(high)CD38(high)) Plasmablasts: A Promising Cellular Biomarker for Immune Activity for Anti-PLA2R1 Related Membranous Nephropathy?
por: Pozdzik, Agnieszka, et al.
Publicado: (2016)

Clinical and immunological implications of increase in CD208(+) dendritic cells in tonsils of patients with immunoglobulin A nephropathy*
por: Takechi, Hanako, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_7bmupinr40j9i2hp0okbd2hltq